Table 1.
Characteristics of included studies
| Study | Intervention, dose (No. of patients) | Country | Mean age (yr) | Baseline IPSS | Study duration (wk) |
|---|---|---|---|---|---|
| Nordling 2005 [9] | Placebo (154), Tamsulosin 0.4 mg (158), Finasteride 5 mg (153), Alfuzosin 10 mg (154), Alfuzosin 15 mg (158) | Denmark | 64.5 | 17.6 | 12 |
| Chapple et al. 2011 [10] | Placebo (190), Tamsulosin 0.4 mg (384), Silodosin 8 mg (381) | UK | 65.9 | 19 | 12 |
| Narayan et al. 1998 [11] | Placebo (239), Tamsulosin 0.4 mg (248), Tamsulosin 0.8 mg (244) | USA | NA | NA | 13 |
| Oelke et al. 2012 [12] | Placebo (172), Tamsulosin 0.4 mg (168), Tadalafil 5 mg (171) | Germany | 63.6 | 17.1 | 12 |
| Lepor 1998 [13] | Placebo (254), Tamsulosin 0.4 mg (254), Tamsulosin 0.8 mg (247) | USA | NA | 19.8 | 13 |
| Kawabe et al. 2006 [14] | Placebo (89), Tamsulosin 0.2 mg (192), Silodosin 4 mg (175) | Japan | 65.6 | 17 | 12 |
| Yokoyama et al. 2013 [15] | Placebo (154), Tamsulosin 0.2 mg (152), Tadalafil 2.5 mg (151), Tadalafil 5 mg (155) | Japan | 63.1 | 16.8 | 12 |
| Kim 2016a) | Placebo (160), Tamsulosin 0.4 mg (152), Tamsulosin 0.2 mg (159) | Korea | NA | 19.9 | 12 |
IPSS, International Prostate Symptoms Score; NA, not available.
a)
American Urological Association 2016 abstract, a randomised, double-blind, phase 3 trial in Korean men.